Skip to main content
. 2023 Jul 13;29(18):3668–3680. doi: 10.1158/1078-0432.CCR-23-0570

Figure 3.

Figure 3. uCGP predicted recurrence risk. Urothelial carcinoma surveillance patients with negative cystoscopy and long-term follow-up with outcomes were analyzed for recurrence risk (n = 55, validation cohort). A, Kaplan–Meier curves for recurrence-free survival by UroAmp-predicted risk. Significance: P = 0.0025 (Log-rank test). B, Univariable Cox proportional-hazard regression analysis of UroAmp recurrence-risk groups and clinical-risk factors. For stage, T1+ indicates the grouping of patients with T1, T2, and T3 disease.

uCGP predicted recurrence risk. Urothelial carcinoma surveillance patients with negative cystoscopy and long-term follow-up with outcomes were analyzed for recurrence risk (n = 55, validation cohort). A, Kaplan–Meier curves for recurrence-free survival by UroAmp-predicted risk. Significance: P = 0.0025 (Log-rank test). B, Univariable Cox proportional-hazard regression analysis of UroAmp recurrence-risk groups and clinical-risk factors. For stage, T1+ indicates the grouping of patients with T1, T2, and T3 disease.